With new products, much of the attention understandably focuses on the launch: development, validation, approval, initial serial delivery and market introduction. When all of this works, the project is considered successful. In my view, however, this is only the beginning of the second—and often much longer—part of the partnership.
The product keeps changing after launch
Medical devices often remain in the market for many years. During that time, almost nothing stays completely unchanged.
Volumes rise or fall. Materials are adjusted. Processes change. Machines are replaced. Supply chains need to be reorganized. Regulatory requirements evolve and design changes become necessary.
This is when the robustness of the original collaboration becomes visible. A good partner can manufacture a product. A very good partner can keep it under control throughout its lifecycle.
Documentation preserves decisions—not just data
Lifecycle capability begins with clean documentation and validated processes. But it also depends on knowledge.
Why was a particular tolerance chosen? Which parameters are truly critical? Which change affects other process steps? Which assumptions were made during the original development?
The answers to these questions carry enormous value. They make it possible to assess later changes faster, avoid repeating old discussions and protect the technical reasoning behind the product.
Lifecycle management is an underestimated CDMO capability
The value of a partnership cannot be measured only by how quickly a New Product Introduction was completed. Equally important is what happens years later.
How quickly can a change be implemented five years after launch? How safely can an additional manufacturing process be introduced? How effectively can a capacity expansion be validated? And how reliably can supply be maintained throughout these changes?
These questions determine whether a product remains manufacturable, compliant and available over the long term.
Long-term partnership requires institutional memory
People change roles, projects move to new teams and equipment evolves. A resilient partnership cannot allow critical knowledge to depend on individual memory alone.
Institutional memory means preserving the context behind technical and regulatory decisions in a form that remains usable years later. It connects documentation, process knowledge and experienced people across the product lifecycle.
This is one of the clearest differences between a strategic partner and an interchangeable supplier.
The launch proves only the first capability
A successful first serial delivery proves that a product can be manufactured. The following years show whether the underlying partnership really works.
The true value of a CDMO becomes visible when change has to be managed without losing control of quality, compliance, cost or supply.
NPI is therefore not the end of the project. It is the foundation for a product lifecycle that may last far longer than the development phase itself.
The first serial order proves that a product can be manufactured. The following years show whether the partnership really works.